N,N-DMT

N,N-DMT (N,N-dimethyltryptamine) is a very short-acting psychedelic tryptamine. In the psychedelic counterculture it is widely known under the nickname The Spirit Molecule, popularised by Rick Strassman's book of that name (2001), which reports on his clinical trials at the University of New Mexico. It is detected at very low concentrations in human body fluids, but its endogenous physiological role remains debated. Synthesised by Richard Manske in 1931, who never tested it in humans, it was the object of the first human studies by Stephen Szára in 1956.

Pharmacology

N,N-DMT is an agonist at the 5-HT2A receptor, with a measured efficacy that varies widely by assay: published Emax values run from 23 to 105 percent, a range covering partial agonism as well as full agonism. Partial agonism is by contrast well established at 5-HT2C in native tissue. Other documented targets include 5-HT1A, 5-HT2B, whose affinity is comparable to or higher than that at 5-HT2A, and the SERT and VMAT2 transporters, for which it is a substrate.

5-HT2A carries most of the subjective effects. 5-HT1A acts as a buffer on overall intensity: in humans, blocking it with pindolol amplifies the experience rather than selectively altering its affective tone. DMT also binds the sigma-1 receptor, but with a dissociation constant of 14.75 µM, two orders of magnitude above its 5-HT1A and 5-HT2A affinities, while human plasma concentrations after a high intravenous dose remain between 0.17 and 1.08 µM: sigma-1 co-activation at psychedelic doses is not established. TAAR1 is activated in rodents, but not at plausible human concentrations. A sigma-1 role in DMT-induced neurogenesis has been reported in mice, while other work routes the plasticity effects through TrkB, mTOR and 5-HT2A: the question remains open.

Taken orally on its own, DMT is inactive through first-pass metabolism, deaminated by MAO-A in the gut wall and liver. The breakdown is not exclusively MAO-dependent, however: after ayahuasca, about 10 percent of the DMT is recovered as the N-oxide, alongside other MAO-independent metabolites.

What actually separates DMT from LSD at the receptor level is not a second target of its own but a narrower profile. LSD binds adrenergic and dopaminergic receptors, which tryptamines do not; DMT interacts with the serotonin transporter, which LSD does not; and its 5-HT2A affinity is markedly lower than that of LSD. To which add a kinetics and a duration that bear no comparison.

Mechanisms

N,N-DMT causes a rapid disintegration of ordinary perceptual models and of predictive filtering. Human data remain limited, but they converge on a decrease in default mode network (DMN) coherence, a marked increase in brain entropy, and a transient reorganisation of sensory integration: increased occipital gamma power, increased connectivity between visual areas and high-level associative cortex, decreased coupling between visual and somatomotor areas. These are human measurements taken under DMT, not extrapolations from psilocybin or LSD.

Beyond the so-called breakthrough threshold, the ordinary model of reality can be replaced almost entirely by a new phenomenological space. The kinetics are abrupt: blood concentrations and subjective effects peak within two minutes, leaving no time for psychological adjustment.

Phenomenology

Beyond breakthrough, perceived reality can be wholly replaced by what is described as a DMT space. One observes a collapse of subjective time (minutes lived as an eternity, looped or outside time), a dissolution of the self and a radical otherness.

At the breakthrough threshold, encounters with entities perceived as autonomous are frequent. Two quantified reference points exist, and their conditions matter as much as their values: 45.5 percent of the 3778 accounts in an unselected corpus, all doses combined, and 34 out of 36 in the only naturalistic study at a controlled dose, whose sample had been recruited among users who had already broken through. The modal mapping, entity-peopled territory against unitive collapse, is detailed on the Breakthrough under N,N-DMT page.

The experience often carries a quality of evidence, revelation or lived truth, along with a short-circuiting of biographical material: the content is often perceived as prior to, or external to, the subject. The rarity of biographical material is measured, at around 2 percent of accounts, and deceased persons are among the rarest contents of all. The noetic quality is very frequently reported in samples made up of people who have already met an entity, with about 69 percent saying they received a message and about 65 percent judging the episode more real than ordinary waking life; in an unselected corpus the proportions are markedly lower, with 31.4 percent of accounts coded as a mystical experience.

Typical subjective effects include complex visions, hyperdense geometry and impossible colours, structured presences and intelligences perceived as autonomous, unusual time (eternity, loop, infinite instant), a sense of the sacred or of ultimate truth, and an abrupt return with material that is hard to put into words.

N,N-DMT holds a singular place: an extremely brief duration (smoked or vaped), yet a phenomenological intensity among the most radical available. Breakthrough is not simply more of the same: it is a qualitative tipping into an autonomous space, often barely biographical and sometimes barely translatable. With ayahuasca (DMT combined with an MAOI), the experience becomes long, more workable while it unfolds, but also more somatically loaded.

Mapping thresholds under N,N-DMT

Threshold 1 - DMN loosening. The DMN doesn't become plastic, not the way it does with LSD: here, more sensory data comes up, top-down priors relax. The world becomes charged with something more, something hard to fully define. Vision sharpens, music breathes, textures inhabit.

Threshold 2 - DMN gives way. Perceptual systems fall apart. Something happens. The real becomes plastic, alien, it melts and reconfigures itself. The ego is dismantled.

Threshold 3 - Entity encounters become likely. This is the breakthrough threshold: presences defying laws that until now held firm, gazes, silhouettes, communication still allusive.

Threshold 4 - Breakthrough. Entity encounters near-certain. No longer a deformed world, but another world opening. Entities dwell there. The ego and the real become the anomaly. The experience here is absolutely alien to the world of Men.

Threshold 5 - At very high doses, or sometimes fortuitously at moderate doses when the system tips over - convergence toward a few stable features: disappearance of entities (they dissolve into something less individuated, or never appear at all), collapse of spatiality, even non-Euclidean spatiality, disappearance of the residual observer (at threshold 4 there almost always remains a thin witness; here, no one left to note that the self has vanished), what reports struggle to name as an ontological rather than spatial infinity. An existence without category, without subject-object distinction, without content. Strassman explicitly contrasts this unitive state with the DMT world he calls interactive, and keeps it apart from entity encounters down to the structure of his book; he reports that such states were very rare in his trials, one volunteer out of nearly sixty. Shanon devotes a full chapter of The Antipodes of the Mind to light, where he describes, at the strongest inebriations, the effacement of the boundary between individual and divine consciousness. Michael, Luke and Robinson (2021) note, across 36 breakthrough accounts, two with no encounter at all, six describing presences without imagery, and five an omnipresence rather than defined beings.

At this point, the N,N-DMT experience converges with that of 5-MeO-DMT: dissolution of form, unitive dissolution, absence of entities, pure non-duality. Some experienced users report very deep, very long, entity-rich breakthroughs without ever tipping into this unitive territory. Others reach it at modest doses. This may not be a matter of depth, but of an alternative neurodynamic trajectory.

Beyond the prototypical opposition

N,N-DMT (entities, geometry, worlds) and 5-MeO-DMT (void, contentless ego death) are often opposed in a convenient but slightly naive way, as if self-dissolution belonged to the latter and mere spectacle to the former. Convergent testimonies and a finer phenomenological reading call for correcting that division.

At breakthrough, the entities and worlds are not a distraction masking the absence of ego death: they are its form. The dissolution here is relational rather than subtractive. The self does not vanish into a void; it loses its monopoly on the subject-pole, and what is perceived (presences, spaces) co-emerges with what remains of it, at equal rank. Mineness is not erased but redistributed: an arrow that no longer points from a single point. This is why such dissolution stays reportable where a pure white-out is mute: 5-HT2A decenters the self-model without switching it off.

Finally, not every dose is the entity-laden breakthrough: depth is graded (see the mapping of thresholds above), and at the deepest threshold the experience converges toward the formless, that is, toward the 5-MeO pole. Entities and void are better read as two forms of the same ownerlessness (relational on one side, unitive on the other) than as content opposed to ego death.

Duration and tolerance

Smoked or vaped (freebase), the effect begins within a few tens of seconds, peaks around one to two minutes, and the whole episode lasts ten to twenty minutes. By the intravenous route, effects peak in under two minutes and are practically resolved by thirty minutes, the early plasma half-life being 5 to 6 minutes. By the intramuscular route (0.2 to 1 mg/kg), onset is two to five minutes and duration thirty to sixty minutes, at lower intensity. With ayahuasca, effects appear within thirty to sixty minutes, peak between an hour and a half and two hours, and are resolved by around four hours; ceremonial sessions commonly run four to six hours because doses are repeated, which is a matter of practice rather than pharmacokinetics.

Tolerance is atypical, and dissociated depending on what is measured. Across four doses of 0.3 mg/kg intravenously spaced thirty minutes apart, no tolerance to subjective effects appears while hormonal responses and heart rate blunt: this is differential tolerance. Under continuous intravenous infusion, by contrast, three recent trials document a moderate acute tolerance to subjective effects, which plateau while plasma concentration keeps rising. No experimental data document cross-tolerance between N,N-DMT and 5-MeO-DMT.

Harm reduction

Transient hypertension, tachycardia and vasoconstriction are possible. DMT's affinity for the 5-HT2B receptor, comparable to or higher than its 5-HT2A affinity, warrants caution with repeated use in people at valvular risk. A history of psychosis or significant cardiac disease is a contraindication.

With an MAOI (ayahuasca, changa, pharmahuasca), interactions are major with SSRIs, SNRIs, MAOIs and stimulants, with a risk of serotonin toxicity. The largest survey of ayahuasca use, covering 10,836 respondents, reports 69.9 percent acute adverse physical effects, mainly vomiting, and 2.3 percent of people who needed medical attention.

The brevity of the smoked route is not a safety margin. Loss of motor control during the first minutes means being seated or lying down, with a sober person present. Breakthrough can be severely taxing without preparation: set and setting are not negotiable. The general principles apply here as elsewhere (see Harm reduction).

Botanically, N,N-DMT occurs in Psychotria viridis, in Mimosa tenuiflora (synonym: Mimosa hostilis) and in certain Acacia species. N,N-DMT and 5-MeO-DMT are distinct molecules: 5-MeO-DMT is far more selective for the 5-HT1A receptor and active at markedly lower doses, and it is that difference in active dose that makes confusing them dangerous.

Three snuff lineages

Amazonian snuffs are routinely described as DMT snuffs. The reference analysis says the opposite. In 1967, Holmstedt and Lindgren examined six snuffs by gas chromatography coupled to mass spectrometry: DMT was identified in five of them and was the main component of none. 5-MeO-DMT is the main component in three, bufotenine in one, and the last contains only beta-carbolines. The work is qualitative, establishing a hierarchy of peaks rather than concentrations; the first quantitative figures for Virola date from 1984.

Three lineages stand apart, and conflating them is the commonest error. The epena snuffs made from Virola are dominated by 5-MeO-DMT and contain no bufotenine. Yopo, cohoba and cebil, made from Anadenanthera, are dominated by bufotenine. Ayahuasca and chacruna alone belong to N,N-DMT. The raw material is not monolithic for all that: in the same work, a Virola calophylla bark is dominated by DMT, and in Piptadenia peregrina the bark and the seeds do not yield the same principal alkaloid. The organ counts as much as the species.

It is in this same volume that the hypothesis which would become pharmahuasca is stated: beta-carbolines, being monoamine oxidase inhibitors, could potentiate the simple indoles. The authors give it as an explicitly undemonstrated conjecture, and one framed for the nasal route. Jonathan Ott confirmed it by self-experiment in 2001.

The first plant in which DMT was found is jurema: in 1946 Oswaldo Gonçalves de Lima isolated, from the root bark of Mimosa hostilis, a partially pure alkaloid he named nigerine; the unambiguous isolation came from Pachter, Zacharias and Ribeiro in 1959.

As for modern use, smoking isolated DMT is attested as an already established practice in January 1967, when Andrew Weil states on the record, in an official United States Public Health Service publication, that people smoke DMT rather than snuff it. The individual paternity often credited to Nick Sand rests on a single retrospective account, published in 2001 and undated.

The archaeology of a vocabulary

The vocabulary in which the DMT experience is spoken has a history, and it is not the one usually told.

The word breakthrough has no identifiable author. Its earliest printed occurrence is from December 1984, in the third of Gracie and Zarkov's Notes from Underground, where it appears in quotation marks and unclaimed, in the very sentence in which the authors do explicitly claim the word chrysanthemum. The word was therefore already circulating orally. No text by Terence McKenna uses it, and its common attribution to McKenna is unfounded: he had a competing vocabulary, the penetration of a membrane. The term only enters peer-reviewed literature around 2021, still in quotation marks and with a purely operational definition.

Three terms do have an author and a date. Chrysanthemum and tryptamine giggles are Gracie and Zarkov's, December 1984; the second named a method, DMT mixed with a herb and smoked gently, explicitly offered to those whom the full effects frightened, which is a named sub-threshold dose category forty years before changa. Carrier wave is Zarkov's, in an account dated 9 October 1984, borrowed from radio vocabulary. Machine elves comes from Terence and Dennis McKenna, The Invisible Landscape, 1975; the fixed phrase self-transforming machine elves appears in a talk given at Esalen in December 1982, where McKenna also offered two forgotten variants, tryptamine Munchkins and fractal elves.

One divergence has never been noted: Gracie and Zarkov did not use the word elves. Zarkov's recurring entities are called banshees, they float, sing reassuring messages and form a doorway. It was McKenna's vocabulary that overwrote theirs.

Nor is tying the entities to fairy folklore a McKenna find. Peter Meyer, in 1992, drew on W. Y. Evans-Wentz's field survey, The Fairy Faith in Celtic Countries (1911). That same text is the forgotten scholarly link in this history: it is Meyer who turns breakthrough into a named stage of a level model, and Meyer who first sets out eight competing ontological readings of the entities without choosing between them.

Before this lexicon, people described it otherwise. Timothy Leary, in 1966, reports on 60 mg intramuscularly without using any of these words: his vocabulary is ecstatic and cellular, jewel-like satori, transcendence of ego and space-time, collapse of learned structure. On the psychiatric side, the Hungarian titles of 1957 and 1958 speak of a psychotic agent and of experiments on psychotics. And as late as 1993, a text circulated on Usenet proposed a competing five-degree scale with its own terminology, which simply lost.

One last point, which explains the loss: the Hyperspace Lexicon, opened in 2009, gives no source, no date and no author for any of its terms, including those whose author is documented.

Endogenous DMT, from psychotoxin to spirit molecule

The history of endogenous DMT begins as a hypothesis about madness, not about the sacred.

As early as 1952, the transmethylation hypothesis proposed that abnormal methylation of an endogenous amine might produce a psychotomimetic compound. DMT was first detected in human fluids in 1965, by Franzen and Gross. The same year saw a paper on a possible endogenous psychotoxin, often cited in connection with DMT: it is in fact about 5-MeO-DMT. The cerebrospinal fluid studies of the late 1970s found no significant difference between people with schizophrenia and controls. The model collapsed in 1976.

The swing toward the sacred dates from 1983, and it is not Strassman's. Two sources in the same year: a lecture by Andrew Weil asserting without reference that the pineal gland almost certainly makes DMT, and a booklet by Albert Most, already the author of the pamphlet on the Sonoran Desert toad, describing an enzymatic conversion of serotonin into a pineal hallucinogen. The original version of the myth is about 5-MeO-DMT. Strassman picked it up and lent it legitimacy later.

The state of the evidence is more unstable than its reputation, in both directions. No quantification of DMT in the human brain exists, by any contemporary technique. The enzymatic pathway routinely cited has been contradicted since 2023: rats lacking INMT retain methylation activity identical to controls, a result published by the very laboratory that had proposed that pathway. And the study most cited by pineal proponents in fact shows that the rat cortex produces DMT independently of the pineal. The review that invalidated the older assays, in 2012, is co-signed by Strassman himself.

David Nichols's 2018 critique rests on two quantitative arguments: the negligible weight of the gland, and the insufficiency of measured concentrations. Barker's reply does not dispute those figures but their relevance, invoking vesicular storage and production in discrete nuclei, while conceding that there is no good estimate of human brain concentration. The controversy is short, dated, and formally closed by an author's reply the same year.

Since 2023 the question has moved ground. The discovery of intracellular 5-HT2A receptors, inaccessible to serotonin but accessible to DMT, shifts the debate from hallucinogenic dose to signalling dose, and DMT is discussed there as a neuromodulator rather than as an endogenous hallucinogen.

On near-death experiences, finally: injected DMT produces an experience that crosses the threshold of the clinical NDE scales, which makes it a good pharmacological model. Nothing establishes that it is the mechanism, and a fine-grained comparison of contents shows that several classic NDE features are absent from DMT.

Sources

• Manske (1931), first synthesis of DMT, within a series of methyltryptamines, with no human trial
• Szára (1956), first human studies. Szára had the compound synthesised, he did not extract it from Mimosa hostilis as is widely claimed; he reports himself having taken up to 250 mg orally with no effect before moving to the intramuscular route
• Efron, Holmstedt and Kline (eds), Ethnopharmacologic Search for Psychoactive Drugs (1967), proceedings of the January 1967 symposium: Holmstedt and Lindgren's analysis of six snuffs, the MAOI hypothesis, and Andrew Weil's mention of DMT already being smoked
• Gracie and Zarkov, DMT: How and Why to Get Off (1984), first printed occurrence of breakthrough, explicit claim to chrysanthemum
• Peter Meyer (1992), first level model and first taxonomy of ontological hypotheses about the entities
• Strassman and Qualls (1994) and Strassman et al. (1994), the UNM trials, dose-response and kinetics
• Strassman (2001), DMT: The Spirit Molecule, Park Street Press (UNM trials 1990-1995, about 400 doses, 60 volunteers)
• Timmermann et al. (2019) and Timmermann et al. (2023), EEG and fMRI under DMT; the measured correlates index the strength of the state, not the content reported
• Lawrence et al. (2022), analysis of 3778 accounts, frequencies of the phenomenological regimes
• Michael, Luke and Robinson (2021), 36 breakthrough accounts at a controlled dose
• Davis et al. (2020), survey of 2561 entity encounters, in a sample made up solely of people who had had one
• Strassman, Qualls and Berg (1996), differential tolerance; Vogt et al. (2023), Luan et al. (2024) and Erne et al. (2025), continuous infusion and moderate acute tolerance
• Zahid et al. (2026), 5-HT1A blockade with pindolol, non-selective amplification
• Barker, McIlhenny and Strassman (2012), review of 69 studies on endogenous DMT, older assays judged probably erroneous
• Dean et al. (2019), extracellular cortical DMT in the rat, independent of the pineal, the authors reserving causal demonstration; Glynos et al. (2023), INMT-KO rats with unchanged methylation
• Nichols (2018), critique of the pineal hypothesis, followed by Barker's reply and the author's response the same year
• Ly et al. (2018) and Morales-García et al. (2020), plasticity, through 5-HT2A, TrkB and mTOR for the former, through sigma-1 for the latter
• Bouso et al. (2022), global ayahuasca survey, 10,836 respondents, adverse effects
• Gallimore and Strassman (2016), modelling of continuous infusion; the protocol extends an immersive state, without establishing that a full breakthrough is maintained